Introduction
============

Background
----------

In the United States, youth living with HIV (YLH)---especially ethnic and racial minority youth and men who have sex with men (MSM)---are experiencing disproportionately high rates of morbidity \[[@ref1]\], which places them at risk for early mortality. Despite the fact that dramatic decreases in HIV transmission are achievable with currently available treatments and interventions (such as antiretroviral treatment \[ART\], pre-exposure prophylaxis \[PrEP\], and rapid and widespread testing), such decreases have not been realized among youth. Only 42% of YLH aged 13 to 24 years are aware of their sero-status, compared with 83.5% of all HIV-positive Americans \[[@ref2]\].

Therefore, it is clear that the HIV health care systems are failing to engage youth at risk for HIV and YLH at one or more steps of the cascade. The HIV prevention cascade includes routine HIV and sexually transmitted infection (STI) testing, as well as PrEP knowledge, access, uptake, and adherence when warranted \[[@ref3]-[@ref5]\]. The HIV treatment cascade describes care for those living with HIV, and includes diagnosis, linkage to care, timely initiation of care, persistence and adherence to ART, and sustained viral suppression.

Even when youth enter the treatment cascade through diagnosis, knowledge of HIV status does not necessarily result in linkage to care. Compared with 75% of adults, less than two-thirds of YLH are linked to care within 6 to 12 months after diagnosis \[[@ref6]\]. Importantly, even linkage to care does not guarantee quality or effective care. The physician must initiate ART early, even if there is erratic behavior on the part of the youth, and YLH must recognize that ART is a lifelong commitment and requires a high degree of adherence. Even with appropriate ART initiation and adherence, drug resistance is present (even at baseline) in approximately 10% of youth \[[@ref7]-[@ref9]\]. Although effectiveness trials report viral suppression rates of 80% or more among YLH receiving ART, observational studies (ie, real-world occurrence) find much lower rates, closer to 50% \[[@ref9]\]. Zanoni and Mayer presented the HIV care cascade of care for adolescent and young adults in the United States with declining numbers for those diagnosed, engaged in medical care, initiated antiretroviral therapy, and achieved viral suppression \[[@ref9]\].

Ultimately, the goal of those involved in HIV prevention and care is to achieve maximum commitment to the HIV prevention and treatment cascades. Mathematical modeling indicates that even with 90% detection of HIV infections, followed by 90% engagement in care of YLH, 90% appropriate treatment of those in care, and 90% viral suppression of treated individuals, approximately 34% of YLH will remain viremic (ie, presence of a virus in the blood) \[[@ref3]\]. In summary, implementation of sustainable service delivery interventions along multiple points in the cascade is necessary to achieve maximal benefits of increased access to ART and increase viral suppression \[[@ref10]\].

To achieve sustained viral suppression, a youth must determine their HIV status and effectively engage in points along the HIV treatment cascade. Engagement should begin at the prevention cascade level, in that youth should have routine HIV testing and consider postexposure prophylaxis or PrEP if warranted. If HIV positive, the youth must immediately engage with the care system, initiate ART and comprehend and embrace the necessity of proper adherence, be retained in care, and maintain viral suppression. Collectively, these steps comprise proper HIV and sexual health self-management, defined as "strategies to help individuals\...and their caregivers better understand and manage their illness and \[/or\] improve their health behaviors" \[[@ref11]\]. Every step of the HIV treatment cascade requires at-risk youth or YLH to make decisions to engage with the system or to modify their behaviors, that is, every step requires active *self-management*. In fact, large numbers of at-risk youth are not seeking HIV/STI testing or other prevention services; if positive, they are not engaging in care. Even when they are in care, many youths are not sustaining adequate HIV care and treatment. They may be engaging in other risky behaviors, such as substance use, that interfere across all points in the cascade.

The Scale It Up (SIU) Research Projects \[[@ref12]\] were funded as part of the Adolescent Medicine Trials Network (ATN) and designed to advance the field of implementation science by employing 3 types of effectiveness implementation hybrid designs, all addressing self-management and inner and outer context variables including sociopolitical culture, organizational characteristics, culture and climate, leadership, dynamics of the multidisciplinary team, facilitator characteristics and attitudes, training fidelity monitoring and support, efforts, intervention fit, and fiscal viability that are involved in successful implementation. SIU utilizes motivational interviewing (MI) to provide a clear framework for improving patient-provider communication and promoting behavior change (ie, improved self-management) using client-centered methods for enhancing motivation and self-efficacy \[[@ref13]\]. These are provider-driven strategies to meet patients where they are currently at regarding behaviors and build motivation for increased change. High-quality patient-provider relationships are associated with a greater likelihood of patients' receiving ART, ART adherence, attending appointments, and having lower viral load \[[@ref14]-[@ref18]\]. Through enhancing implementation of treatment protocols and patient-provider relationships, SIU focuses on improving youths' outcomes along the prevention and care cascades. Examining trends in the care cascade is therefore critical for providing a foundation for outcomes assessment across SIU projects.

Cascade monitoring (CM) ATN 154 is a center-wide protocol in SIU focusing on the HIV care cascade as well as health factors (eg, cardiovascular functioning) known to be consequential for the long-term health outcomes of individuals living with HIV. Information collected in CM will monitor impact from other SIU protocols on potential gains in the treatment cascade. CM specifically collects only data that can be extracted from electronic health records (EHRs); therefore, CM does not include HIV prevention data, as the participating clinical sites generally did not have prevention data available for extraction. Documenting trends in the care cascade will facilitate a deeper comprehension of when in the care cascade patients most commonly drop out, and what populations commonly disengage from the cascade, thereby providing researchers, clinicians, and community stakeholders a pulse on the adolescent HIV epidemic. Furthermore, the use of electronically extracted variables that measure general patient conditions by International Statistical Classification of Diseases and Related Health Problems-10th revision (ICD-10) codes, as well as cascade-specific variables, enables us to identify clusters of data points that are meaningful for monitoring differences in treatment cascade retention. These clusters of EHR variables, called informatics *EHR phenotypes*, can then be used to identify similar patients in other electronic data systems. The EHR phenotypes identified for YLH through CM will be used in the cost-effectiveness analysis for the SIU studies and used with large archival databases to estimate the prevalence of cascade failures to YLH in other community settings not included in the CM study.

Aims
----

CM provides an opportunity to assess trends to guide new protocol development and to facilitate community engagement. These data will support the Adolescent Medicine Trials Network (ATN) to have a finger on the pulse of the epidemic and will provide feedback to sites and community partners. Using the EHR phenotypes from CM, the patterns observed in the 10 SIU clinical sites can be extended to identify YLH in other settings, which can help policymakers and service providers improve systems and services and address barriers to care to better support individuals as they move from one step in the HIV care continuum to the next.

-   Aim 1: Develop a common data model of variables of relevance for measuring cascade outcomes across 10 multidisciplinary adolescent HIV clinics and implement EHR data extraction (downloading) annually for 2016 to 2021 calendar years.

-   Aim 2: Utilize data submission reports to identify a systematic EHR data extraction process to be utilized by clinic sites.

-   Aim 3: Using extracted EHR data, determine how many of those retained in care and receiving ART keep clinic appointments and achieve viral suppression.

-   Aim 4A: Determine when patients most commonly drop out of the HIV care continuum, and what populations commonly do so, in the SIU clinical sites.

-   Aim 4B: Develop a phenotype for HIV-infected adolescents from the EHR CM data. Use the phenotypes applied to large national datasets to estimate variations in rates of cascade failure for YLH in the United States to help policymakers and service providers improve systems and services to better support individuals as they move from one step in the HIV care continuum to the next.

-   Aim 5: Measure the effect of clinic-based interventions in SIU on longitudinal HIV care cascade outcomes across the 10 multidisciplinary adolescent HIV care clinics (approximately 1200 patients). This center-wide protocol will support the aims of the separate SIU projects.

-   Aim 6: Apply the phenotype for HIV-infected adolescents from the EHR CM data to national databases to estimate costs weights for use in the assessment of cost-effectiveness of the SIU interventions.

Methods
=======

Overview
--------

This study (CM, ATN 154) is part of the SIU program as described in the overview paper in this issue \[[@ref12]\]. Deidentified EHR data will be collected retrospectively from 10 clinical sites, also known as Subject Recruitment Venues (SRVs), participating in the SIU. The sites are as follows:

1.  Site 1: Baltimore---Johns Hopkins University, Maryland.

2.  Site 2: Birmingham---University of Alabama at Birmingham, Alabama.

3.  Site 3: Brooklyn---SUNY Downstate Medical Center, New York.

4.  Site 6: Los Angeles---Children's Hospital Los Angeles, California.

5.  Site 7: Memphis---St. Jude Children's Research Hospital, Tennessee.

6.  Site 8: Miami---University of Miami, Florida.

7.  Site 10: Philadelphia---Children's Hospital of Philadelphia, Pennsylvania.

8.  Site 11: San Diego---University of California San Diego, California.

9.  Site 12: Tampa---University of South Florida, Florida.

10. Site 13: Washington, DC---Children's National Health System, District of Columbia.

The first extracts will contain standard of care and treatment visits in the full year of 2016 and associated data (see [Table 1](#table1){ref-type="table"}) for all YLH, aged 15 to 24 years, treated at sites. Subsequently, 1-year data extracts will be requested from sites annually, with the final year of data uploaded in 2022 for the full year of 2021 (see [Figure 1](#figure1){ref-type="fig"}).

Data Acquisition
----------------

Data collection will occur at all SIU clinical sites providing care to YLH by site personnel. The scientific and leadership teams have determined that there will not be resources allotted to do chart review for the CM measures; therefore, the CM protocol team will receive only measures available for extraction from the clinics' electronic data systems. The provision of electronically downloaded data, relative to hand extracted, also reduces the risk of data entry error, particularly for complex variables (eg, ICD-10 codes). However, given that longitudinal surveillance of viral load is critical to the success of the protocol, hand-extracted viral load data are the only exception when it cannot be electronically downloaded. All data transferred by the sites to the CM protocol team will be deidentified at the sites before data transfer. Having the sites create and update a master list of patients and unique identifiers is crucial for conducting longitudinal data analysis and following patient attributes and outcomes over time. Sites will be provided with the instructions on the unique identifiers that should be used to create participant identification numbers.

###### 

Measures.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Type and variable    Metrics and notes                                                                                                
  -------------------- ---------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------
  **Time varying**                                                                                                                      

  \                    Patient ID                                                                                                       Unique to study, should not match patient's medical record file (ie, deidentified); see table below

  \                    Visit date                                                                                                       MM/DD/YYYY

  \                    Antiretroviral Medications---Name                                                                                Name of medication; include all prescribed

  \                    Viral load results                                                                                               Quantitative value (parts per cubic ml)

  \                    CD4 cell count result                                                                                            Absolute count

  \                    Height                                                                                                           Meters

  \                    Weight                                                                                                           Kg

  \                    Blood pressure---systolic                                                                                        mmHg

  \                    Blood pressure---diastolic                                                                                       mmHg

  \                    Cholesterol panel---total                                                                                        mg/dL

  \                    Cholesterol panel---low density lipoprotein                                                                      mg/dL

  \                    Cholesterol panel---high density lipoprotein                                                                     mg/dL

  \                    Cholesterol panel---triglycerides                                                                                mg/dL

  \                    Blood glucose---hemoglobin A~1c~                                                                                 mg/dL

  \                    Blood glucose---fasting                                                                                          mg/dL

  \                    Tobacco use---current status                                                                                     current/past/never

  \                    Tobacco use---how much                                                                                           Number of packs per day

  \                    Tobacco use---how long                                                                                           Number of years

  \                    Chlamydia test result                                                                                            Positive/negative OR reactive/nonreactive; if titer please enter positive or reactive

  \                    Gonorrhea test result                                                                                            Positive/negative OR reactive/nonreactive; if titer please enter positive or reactive

  \                    Herpes test result                                                                                               Positive/negative OR reactive/nonreactive; if titer please enter positive or reactive

  \                    Syphilis test result                                                                                             Positive/negative OR reactive/nonreactive; if titer please enter positive or reactive

  \                    Human papilloma virus test result                                                                                Positive/negative OR reactive/nonreactive; if titer please enter positive or reactive

  \                    Other non-HIV medication---Name                                                                                  Name of medication; include all prescribed

  \                    Patient zip code                                                                                                 Last known/documented

  \                    International Statistical Classification of Diseases and Related Health Problems-10th revision Diagnoses Codes   Include all from visit; extracted as left-hand justified character variables

  \                    CPT^a^-4 Procedure Codes                                                                                         Include all from visit; extracted as 5-digit numerical variables

  \                    Health care common procedure coding system Procedure Codes                                                       Include all from visit; if used instead of CPT codes; extracted as 5-digit character variable

  **Time invariant**                                                                                                                    

  \                    Patient ID                                                                                                       Unique to study, should not match patient's medical record file (ie, deidentified)

  \                    Current age                                                                                                      Age as of January 1 of the year of data download (eg, 01/01/2016 for 2016 data download)

  \                    Age at HIV diagnosis                                                                                             Years

  \                    Date of HIV diagnosis                                                                                            MM/DD/YYYY

  \                    Gender                                                                                                           Self-report; for example, male, female, transgender male-to-female, transgender female-to-male, other

  \                    Race                                                                                                             Self-report

  \                    Ethnicity                                                                                                        Hispanic/non-Hispanic/other as available /self-report

  \                    Sexual-orientation                                                                                               Self-report

  \                    Mode of transmission                                                                                             For example, men who have sex with men, intravenous drug use, high-risk heterosexual

  \                    Date of entry into care                                                                                          MM/DD/YYYY

  \                    Date of death (if applicable)                                                                                    MM/DD/YYYY
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^CPT: Current Procedural Terminology.

![Cascade monitoring study design.](resprot_v8i5e11185_fig1){#figure1}

The SIU Recruitment and Enrollment Center (REC) is a subsidiary of the management core and works with the CM protocol team to communicate and work with SRVs to obtain EHR data and troubleshoot challenges. The REC issues launch materials including example templates to sites before download, specifying data elements, formats, and ordering. Data structure will likely vary by site and depend on the resources and capabilities of each site. The REC is equipped to process various data structures and formats, in this case.

The CM protocol requires data to be electronically downloaded, not hand-extracted. If a site cannot, at a minimum, download viral load, date of appointment, age, height, weight and ICD-10 diagnoses codes, then the CM protocol team will consider dropping the site. The site needs to discuss with their information technology team/department to determine if downloading is possible, and any associated cost. The CM protocol team will then determine whether it is feasible for the site to remain as part of CM and, if applicable, an acceptable date of data transfer.

EHR data on cost-effectiveness variables include ICD-10 diagnoses codes (extracted as left-hand justified character variables), current procedural terminology (version 4) procedure codes (extracted as 5-digit numerical variables), and health care common procedure coding system procedure codes (if used instead of CPT codes; extracted as 5-digit character variables). A data explanation form is used to document information relevant to the conduct of the study that is not captured on other study forms (eg, explanation for missing variables or explanation for using a different metric than the one specified in the study summary). This form also includes a column for sites to indicate which method they used to obtain the data (ie, hand extraction for viral load only vs downloaded).

Data Transfer
-------------

Data transfer will occur annually as site data extracts are uploaded and processed. Dropbox Business software will be utilized to allow for the transfer of relevant data files from sites to the REC and from the REC to the CM protocol leads and analytic core (AC) that are encrypted and meet all standards for Health Insurance Portability and Accountability Act (HIPAA) compliance. The Dropbox Business program and its rigorous HIPAA-compliant system for managing the sharing of individual folders will allow for the development of permissions that restrict access to each file to site-specific personnel, protecting participant confidentiality. The system uses a combination of user authentication, file audit trails, device and user permissions, emergency access protocols, and login/logoff checks to manage the integrity of files. The Dropbox Business program encrypts each file uploaded onto the Dropbox servers and then, with the appropriate permissions via *keys*, allows users to download and unencrypt the file on their local machine. This means that all files stored on Dropbox are completely encrypted such that anyone without the appropriate *key* on their local machine will be unable to open the file after downloading it---this process can be done live through shared folders or through Web-based file delivery (similar to a file transfer protocol delivery). To upload, a user drags and drops files to the appropriate folder or selects them via the menu, just as they normally would. As Dropbox Business will be used for data storage and the software employs secure encryption upon upload and Secure Sockets Layer (SSL) for data transmission, device encryption is not required at the sites.

Regarding Dropbox Business and encryption, the key features of Dropbox Business (a HIPAA-compliant cloud encryption software) are as follows:

1.  Dropbox employs file-level encryption on devices and the cloud with Advanced Encryption Standard 256-bit encryption and uses SSL for transmission.

2.  Any file placed in Dropbox is automatically encrypted. As Dropbox synchronizes only encrypted versions of files, the data are consistently protected.

Data transfer will occur annually, as site data extracts are uploaded and processed.

Data Storage
------------

Dropbox Business will be the primary method of data storage, and data files will be uploaded and downloaded securely by the REC, CM protocol lead and colead, and AC. Data files will not be saved on local machines under any circumstances. Regarding analyses, data will be analyzed by the CM protocol team and the AC using secure computer systems.

Data Management
---------------

The protocol lead and colead will provide data management support for the AC, working closely with the clinical sites and the management core. One of their roles is specifically management of EHRs to develop a common data model across all 10 clinical sites.

The leads will ensure that analysis-ready datasets are regularly produced for the AC through ongoing data management. They will consult with the scientific team and with the AC to create a data management protocol, which details how finalized data will be structured. The data management protocol will be used in conjunction with the variable codebook to guide the data management process. Data will be exported from relevant sources and then imported into Statistical Analysis System (SAS Institute) and IBM Statistical Package for the Social Sciences (SPSS Inc). Using both SAS and SPSS, the leads will develop automated syntax files that will be used to clean data files by calculating scale scores, recoding variables, addressing missing data, and merging datasets together. Final datasets will be delivered to the AC in a preferred file format (SPSS, SAS, or CSV). Protocol leads will also provide ongoing support for cleaned data and perform additional data cleaning tasks as requested by the AC.

Data Analysis Plan
------------------

Upon initial receipt of the data and at regular intervals, exploratory data analysis will be conducted to understand the breadth and specificity of available data. Descriptive statistics, including measures of central tendency, will be generated to identify outliers and track data consistency for future downloads. For the ATN as a whole, and also for sites individually, the proportion of individuals in each key stage of the cascade (retained in care, prescribed ART, and virally suppressed) will be described at baseline and over time.

The AC will perform longitudinal data analyses with advanced analytic procedures such as mixed-effects regression models, generalized estimation equations with a Poisson distribution, and log link function to model care retention based on both patient-related and clinical characteristics to identify the relevant predictors associated with dropout at any stage of the cascade. Moreover, these models will be utilized to identify trends and patterns of change over the course of data collection. We will also conduct additional analyses to assess baseline differences among sites as a function of previous training or participation in ATN studies. On the basis of the findings, the AC will provide suggestions to the SIU leadership, the protocol leads, sites, and community partners to support ATN protocols and development going forward.

### Cost-Effectiveness Analysis Plan

The AC will specify costs of implementation for budgeting further scale up of SIU interventions but will also identify the incremental benefit of SIU interventions on cascade outcomes over time. The cost-effectiveness analysis for the study is designed to measure costs and consequences of changes in the implementation over the 48 months of study follow-up. Furthermore, the goal is to help inform the investigators of the economic consequences of the varying amount of resources used in the exploration, preparation, implementation, and sustainability components of the study \[[@ref19]\]. The data collected through the CM study and the resulting EHR phenotypes for YLH will be used to construct episode costs from large billing databases that are relevant for modeling the cost-effectiveness of interventions aimed at YLH. The AC will use a previously developed cost utility model to estimate the cost per quality-adjusted life year over a 10-year time horizon expected from cascade outcomes of viral suppression and retention in care. As part of the identification of the larger cost-of-illness burden of cascade lapses for YLH, we will use the EHR phenotypes and archival data from Medicaid and/or privately insured populations to model the extent of cascade interruptions present in other practice settings. The data will be combined with the individual cost weights to estimate the variations in the economic burden that cascade disruptions for YLH place on US communities.

Results
=======

The first year of data extraction for the 2016 data was launched on December 4, 2017, in 10 nationwide clinic sites. The REC sent launch emails to each site with instructions for data formatting and transfer, as well as created individual Dropbox Business accounts for each site to ensure secure transfer and storage of data. Sites varied in the length of time to obtain and download data (from 2 months to 6 months post study launch). All sites successfully uploaded data by May of 2018; all sites were asked to download the following: age as of January 1, 2016, appointment dates, viral load, ICD-10 diagnoses codes, height, and weight. Additional variables were downloaded if available for electronic extraction, such as STI test results, cholesterol panel, race, and CD4 counts. In total, 70% of the sites provided data for all mandatory variables via electronic download. The remaining sites will provide data for all mandatory variables via electronic and hand extraction in the future. These variables may include various lab tests, gender, race/ethnicity, and weight. Therefore, we will have complete information for all mandatory variables from all sites for future data submissions. Although a few sites were not able to electronically download demographic information and specific lab results, the protocol team worked with each site to develop a plan for hand extraction of those variables.

The second year of data extraction for 2017 data was launched during October of 2018. The deadline for site data submission is scheduled for December of 2018. Subsequent data extractions will take place yearly in October through 2021. Data for the years of 2016 through 2021 will be available for data analysis as requested by specific SIU protocol team.

These uploads mark significant progress toward protocol goals to examine trends in the HIV treatment cascade. Through preliminary evaluation of uploaded data and correspondence with sites through the SIU Website's Support Request Form system, the REC has learned valuable information that will facilitate the ATN's extended knowledge on the pulse of the epidemic.

Discussion
==========

Summary of Key Innovations
--------------------------

This study has several strengths. One is its sample size---by capturing data from 10 different clinic sites across the nation, it creates a robust dataset of YLH in the HIV treatment cascade. Moreover, the longitudinal design increases the amount of data available across the 10 sites and allows tracking youths' progress over time, including an understanding of those who enter or exit the system between 2016 and 2021.

The longitudinal data also allow the SIU scientific team to track the impact of SIU clinic-based interventions, including ATN 146, Tailored Motivational Interviewing Implementation Intervention \[[@ref20]\]. The EHR is beneficial as it reduces secondary data entry error when creating data files shared between sites and SIU personnel and does not rely on youth self-report of health. This is especially crucial for YLH, who may not yet be familiar with the details and nuances of their health information. With EHR data, we are able to obtain data that are specific and verified and gathered relatively quickly in large quantities. With the development of the phenotypes, we will be able to extend our study findings to identify lapses in the treatment cascade for YLH using large national databases. This process will permit the enumeration of this patient phenotype nationwide and the description of related annual economic costs of care. This will enable us to identify meaningful variations between communities that can then serve as the basis for targeting interventions.

Finally, the method through which we receive data is also secure and safe for participants. All datasets are deidentified at the clinic sites thereby minimizing risks to breach of confidentiality. Using Dropbox Business further secures patient data, as the service encrypts all data and is HIPAA compliant.

Limitations and Conclusions
---------------------------

Despite significant benefits and innovation, study limitations exist. First, although there are 10 ATN clinic sites participating in this study, the majority of them are located in the Eastern part of the United States. There are only 2 sites west of Memphis and both (Los Angeles and San Diego) are in California. As a result, YLH who live in other parts of the United States, mainly the Midwest, Southwest, and West, are not included in this study. In addition, all clinics are situated in major cities. YLH living in smaller cities or in rural areas are also excluded. This potentially biases the sample, as YLH in nonurban areas experience different barriers to accessing and staying in care. For instance, those in urban areas may have greater access to public transportation and do not have to rely on cars or parking to visit a clinic. In addition, those in nonurban areas may have fewer clinics nearby, experience greater stigma from their community, or receive less structural support (in the form of policy or provider availability) for HIV-related care. Finally, the ATN clinics themselves are located within major academic research institutions. This suggests that the providers have more funding and support, as well as greater ability to adopt new evidence-based practices, than those without university support. As a result, the outcomes from this study will likely represent the best-case scenario for YLH in treatment. However, this limitation will be modified somewhat because of our plan to use the CM-developed EHR phenotypes to document cascade variations among communities represented by large archival databases, such as data from Medicaid and private insurers. Although such assessments will have errors and omissions at the level of individual patients, these analyses will provide important data at the population level. Even with the extended modeling, our findings will still be limited by the fact that the YLH in our CM study and by extension in the large national databases already know their status and have entered the HIV treatment cascade. There are many YLH who are still unaware of their sero-status or may not have the means or ability to seek care. This particular study is only able to investigate YLH who have already engaged in care in some way.

Despite these limitations, this study has the capacity to provide a wealth of crucial data for improving our understanding of YLH and their engagement in the HIV treatment cascade. Specifically, data from this study will indicate patterns of youths' engagement in care across 10 different clinic sites and the manner in which this population changes over the course of 6 years. This research has the ability to provide high-quality data on trends in the HIV treatment cascade; specifically, how many of those retained in care and receiving ART adhere to their treatment plan and achieve viral suppression. Likewise, it will be possible to determine who falls out of treatment, providing clinics and policymakers critical information for how to better support these communities. These data will also be crucial for measuring the effect MI has on YLH outcomes over time.
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